Qiagen (QGEN) Upgraded to “Hold” by BidaskClub

Qiagen (NASDAQ:QGEN) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday.

Several other equities analysts have also weighed in on QGEN. Evercore ISI assumed coverage on shares of Qiagen in a report on Wednesday. They set an “outperform” rating and a $35.00 target price on the stock. Cowen restated a “hold” rating and set a $33.00 target price on shares of Qiagen in a report on Thursday, September 28th. DZ Bank restated a “neutral” rating on shares of Qiagen in a report on Tuesday, December 19th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Finally, Commerzbank restated a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $34.63.

Shares of Qiagen (NASDAQ QGEN) traded up $0.22 on Friday, hitting $32.46. 966,446 shares of the company’s stock were exchanged, compared to its average volume of 888,525. The firm has a market cap of $7,490.00, a price-to-earnings ratio of 83.23, a PEG ratio of 1.77 and a beta of 1.10. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33.

Qiagen (NASDAQ:QGEN) last posted its earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. The business had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.29 EPS. equities research analysts anticipate that Qiagen will post 1.25 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Qiagen by 4.6% during the 2nd quarter. BlackRock Inc. now owns 8,203,013 shares of the company’s stock worth $275,048,000 after buying an additional 363,377 shares during the period. Vanguard Group Inc. increased its stake in Qiagen by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock worth $202,986,000 after buying an additional 394,201 shares during the period. Frontier Capital Management Co. LLC increased its stake in Qiagen by 0.7% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 2,554,021 shares of the company’s stock worth $80,452,000 after buying an additional 17,946 shares during the period. State Street Corp increased its stake in Qiagen by 2.1% during the 2nd quarter. State Street Corp now owns 2,330,061 shares of the company’s stock worth $78,130,000 after buying an additional 48,679 shares during the period. Finally, Legal & General Group Plc increased its stake in Qiagen by 0.8% during the 3rd quarter. Legal & General Group Plc now owns 1,909,956 shares of the company’s stock worth $52,573,000 after buying an additional 15,660 shares during the period. 62.24% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Qiagen (QGEN) Upgraded to “Hold” by BidaskClub” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/qiagen-qgen-upgraded-to-hold-by-bidaskclub.html.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply